诺和锐和普通胰岛素治疗2型糖尿病的临床比较
 |
| 第1页 |
参见附件。
[摘要]目的：比较2型糖尿病患者应用超短效人胰岛素类似物诺和锐和普通胰岛素强化降糖的疗效。方法：80例患者随机分为2组，诺和锐组用诺和锐联合甘精胰岛素治疗，普通胰岛素组用普通胰岛素联合甘精胰岛素治疗。观察两组患者血糖达标时间，达标时日均胰岛素用量，住院总费用及低血糖发生情况。结果：诺和锐组血糖达标时间，胰岛素日用量及低血糖发生均低于普通胰岛素组(P<0.05)，但住院总费用两组无统计学差异(P>0.05)。结论：诺和锐疗效优于普通胰岛素，且住院总费用并不高于普通胰岛素。
[关键词]诺和锐；普通胰岛素；糖尿病，2型
[Abstract]Objective：To compare the clinical effect and safety of Aspart and Regular insulin in treating type 2 diabetes mellitus(T2DM). Methods：80 cases of T2DM were divided into two groups at random，Aspart group(AG) and the regular insulin group(RG). The Insulin glargine was used in two groups. The therapeutic time， the average insulin dose in day，the hospitallization expenses and adverse reaction were observed. Results：The therapeutic time， the average insulin dose in day and adverse reaction in AG were lower than in RG(P<0.05). But the hospitallization expenses had no difference in two groups(P>0.05). Conclusion：Aspart is effective ......
您现在查看是摘要介绍页，详见PDF附件。